オピオイド使用障害 (OUD) 市場レポート：動向、予測、競合分析 (2030年まで)

オピオイド使用障害 (OUD) の動向と予測

世界のオピオイド使用障害 (OUD) 市場の将来は、病院薬局と小売薬局市場に機会があり、有望視されています。世界のオピオイド使用障害 (OUD) 市場は、2024年から2030年までのCAGRが10.3%で、2030年までに推定72億米ドルに達すると予測されます。この市場の主な促進要因は、がん、心血管疾患、整形外科疾患などの慢性疾患の有病率の増加と、ブプレノルフィンパッチが効率的な治療オプションとして認知されつつあることです。

• Lucintelの予測では、薬剤の種類別では、高齢化人口の増加とオピオイド乱用の有病率の増加により、アゴニストが予測期間中も大きなセグメントを維持します。
• 流通チャネル別では、医療インフラ整備のための政府支出の増加により、病院薬局が引き続き大きなセグメントとなると思われます。
• 地域別では、オピオイド乱用治療薬の上市・承認数の増加により、北米が予測期間中最大の地域であり続けると思われます。

オピオイド使用障害 (OUD) 市場の戦略的成長機会

オピオイド使用障害 (OUD) 市場は、さまざまな用途においていくつかの戦略的成長機会を提示しています。これらの機会を活用することで、治療成果を高め、アクセスを拡大し、進行中のオピオイド危機に効果的に対処することができます。

• MATプログラムの拡大：十分な治療を受けていない地域への薬物療法支援プログラムの拡大は、大きな成長の可能性をもたらします。ブプレノルフィンやメタドンなどのMATの選択肢を増やすことで、OUDに苦しむ人々の効果的な治療へのアクセスを改善することができます。
• デジタルヘルスソリューションの統合：遠隔医療やモバイルアプリを含むデジタルヘルスソリューションの統合は、成長の機会を提供します。これらのツールは治療の提供、患者の関与、モニタリングを強化し、市場拡大の新たな道を開く。
• 新規治療法の開発：新薬の製剤や併用療法など、新規治療法の研究開発への投資は成長機会をもたらします。アンメットニーズに対応する革新的な治療法は、市場シェアを獲得し、治療選択肢を改善することができます。
• ハームリダクション・プログラムの拡大：注射針交換サービスや監視付き消費サイトなど、有害物質削減プログラムの拡大には成長機会があります。これらのプログラムは、オピオイド使用の影響を軽減し、治療と回復への道筋を提供することができます。
• 統合ケアモデルの強化：OUD治療とメンタルヘルスや社会的支援サービスを組み合わせた統合ケアモデルの開発と実施は、成長の可能性をもたらします。こうしたモデルは患者の転帰を改善し、OUD患者の多面的なニーズに対応します。

OUD市場における戦略的成長機会には、MATプログラムの拡大、デジタルヘルスソリューションの統合、新規治療法の開発、ハームリダクション・イニシアチブの拡大、統合ケアモデルの強化などが含まれます。これらの機会は、市場の進化するニーズに合致しており、治療と回復の成果の大幅な改善を促進することができます。

オピオイド使用障害 (OUD) 市場促進要因・課題

オピオイド使用障害 (OUD) 市場は、技術の進歩、経済要因、規制の変更など、さまざまな促進要因・課題によって大きな影響を受けます。促進要因には、治療選択肢の革新、認知度の向上、政策改革、経済的インセンティブ、治療へのアクセス改善などがあります。一方、課題には、規制のハードル、経済的障壁、治療のアドヒアランスとアクセシビリティに関する問題が含まれます。これらの要因を理解することは、OUD市場の複雑さを乗り越え、効果的な治療と管理のための戦略強化を目指す利害関係者にとって極めて重要です。

オピオイド使用障害 (OUD) 市場を牽引する要因は以下の通りです：

1.技術の進歩：デジタルヘルスツールや高度な薬物処方などの治療技術の革新が、OUD市場の成長を促進しています。デジタルプラットフォームは、遠隔モニタリング、遠隔医療、個別化された治療計画を容易にし、患者の関与と転帰を改善します。徐放性オプションを含む新しい薬剤製剤は、治療の有効性と利便性を高め、市場の需要拡大に寄与しています。

2.意識と教育の向上：オピオイド危機とOUDに対する意識の高まりは、効果的な治療に対する需要の増加につながりました。教育キャンペーンや公衆衛生への取り組みは、オピオイド中毒に対する理解を深め、偏見をなくし、治療を受けるよう促しています。このような意識の高まりは、OUD管理ソリューションの必要性をより多くの人々が認識するようになり、市場成長の原動力となっています。

3.政策と規制の改革：政策と政策の変化別、OUD治療へのアクセスが向上しています。薬物補助療法 (MAT) の保険適用拡大や支援法などの政府の取り組みは、治療への障壁を減らしています。これらの改革は、医療提供者に幅広い治療選択肢を提供することを促し、患者の全体的なアクセスを改善しています。

4.経済的インセンティブと資金援助：政府や民間からの資金援助が増加し、OUD治療プログラムや調査を支援しています。MATに対する助成金や中毒治療施設に対する助成金などの経済的インセンティブにより、医療提供者は包括的な治療を提供しやすくなっています。このような経済的支援は、治療の可用性と革新性を高め、市場の成長を促しています。

5.治療アクセスの拡大：特に医療サービスが行き届いていない地域や地方におけるOUD治療へのアクセス拡大への取り組みが、市場成長を後押ししています。治療センターの数を増やし、移動式治療ユニットを提供し、プライマリー・ヘルス・サービスに治療を統合する取り組みが、アクセスの利便性を向上させています。こうした取り組みにより、より多くの人々がOUDの管理に必要なケアを受けられるようになっています。

オピオイド使用障害 (OUD) 市場における課題は以下の通りです：

1.規制上のハードル：複雑な規制要件を乗り越え、新たな治療法の承認を得ることは困難です。地域別規制が異なるため、革新的な治療法の市場参入が遅れ、普及の障壁となる可能性があります。また、厳格なガイドラインへの準拠は、メーカーのコストを増加させ、治療法の利用を制限する可能性があります。

2.経済的障壁：薬や治療プログラムを含むOUD治療に関連する高額な費用は、大きな障壁となり得ます。経済的制約は、必要な治療への患者のアクセスを制限し、治療のアドヒアランスに影響を及ぼす可能性があります。不十分な保険適用や自己負担額は、こうした課題をさらに悪化させ、市場全体の成長に影響を与える可能性があります。

3.治療アドヒアランスとアクセシビリティの問題：一貫した治療アドヒアランスの確保とアクセシビリティの問題への対応は大きな課題です。患者は副作用、スティグマ、サポート不足のためにアドヒアランスに苦労する可能性があります。特に遠隔地では、治療センターを利用できる場所が限られていることも、アクセスを妨げ、OUD管理の取り組みの効果に影響を与える可能性があります。

オピオイド使用障害市場は、市場促進要因・課題が複雑に絡み合って形成されています。技術の進歩、認知度の向上、政策改革、経済的インセンティブ、アクセスの拡大は、治療の有効性と利用可能性を高める主要な促進要因です。しかし、規制のハードル、経済的障壁、治療のアドヒアランスとアクセシビリティの問題は、大きな課題となっています。これらの要因に対処することは、市場戦略を最適化し、オピオイド使用障害に罹患した人々の転帰を改善するために極めて重要です。OUD治療の展望を前進させようとする利害関係者にとって、これらの力学を理解し、うまく乗り切ることは不可欠でしょう。

目次

第1章 エグゼクティブサマリー

第2章 世界のオピオイド使用障害 (OUD) 市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 市場動向と予測分析 (2018年～2030年)

• マクロ経済動向 (2018～2023年) と予測 (2024～2030年)
• 世界のオピオイド使用障害 (OUD) 市場の動向 (2018～2023年) と予測 (2024～2030年)
• 世界のオピオイド使用障害 (OUD) 市場：薬剤の種類別
  • 作動薬 (アゴニスト)
  • 拮抗薬 (アンタゴニスト)
• 世界のオピオイド使用障害 (OUD) 市場：年齢層別
  • 19～39歳
  • 40～59歳
  • 60歳以上
• 世界のオピオイド使用障害 (OUD) 市場：投与経路別
  • 経口
  • 静脈内
  • 舌下
• 世界のオピオイド使用障害 (OUD) 市場：流通チャネル別
  • 病院薬局
  • 小売薬局

第4章 地域別の市場動向と予測分析 (2018年～2030年)

• 世界のオピオイド使用障害 (OUD) 市場：地域別
• 北米のオピオイド使用障害 (OUD) 市場
• 欧州のオピオイド使用障害 (OUD) 市場
• アジア太平洋のオピオイド使用障害 (OUD) 市場
• その他地域のオピオイド使用障害 (OUD) 市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界のオピオイド使用障害 (OUD) 市場の成長機会：薬剤の種類別
  • 世界のオピオイド使用障害 (OUD) 市場の成長機会：年齢層別
  • 世界のオピオイド使用障害 (OUD) 市場の成長機会：投与経路別
  • 世界のオピオイド使用障害 (OUD) 市場の成長機会：流通チャネル別
  • 世界のオピオイド使用障害 (OUD) 市場の成長機会：地域別
• 世界のオピオイド使用障害 (OUD) 市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のオピオイド使用障害 (OUD) 市場の生産能力拡大
  • 世界のオピオイド使用障害 (OUD) 市場における企業合併・買収 (M&A)、合弁事業
  • 認証とライセンシング

第7章 主要企業のプロファイル

• Hikma Pharmaceuticals
• Indivior
• Titan Pharmaceuticals
• Reckitt Benckiser Pharmaceuticals
• Camurus
• BioDelivery Sciences International
• Sandoz

Opioid Use Disorder (OUD) Trends and Forecast

The future of the global opioid use disorder (OUD) market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets. The global opioid use disorder (OUD) market is expected to reach an estimated $7.2 billion by 2030 with a CAGR of 10.3% from 2024 to 2030. The major drivers for this market are the growing prevalence of chronic diseases, such as cancer, cardiovascular diseases, and orthopedic diseases, and the increasing recognition of buprenorphine patches as an efficient treatment option.

• Lucintel forecasts that, within the drug type category, agonists will remain the larger segment over the forecast period due to the growing aging population and increase in the prevalence of opioid abuse.
• Within the distribution channel category, hospital pharmacies will remain the larger segment due to rising expenditure by the government to develop healthcare infrastructure.
• In terms of regions, North America will remain the largest region over the forecast period due to a rise in the number of product launches and product approval for opioid use disorder.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Opioid Use Disorder (OUD) Market

Emerging trends in the opioid use disorder (OUD) market are shaping the future of treatment with advancements in medication, technology, and holistic approaches. These trends reflect a shift towards more comprehensive and personalized care strategies.

• Increased Use of Digital Health Technologies: Digital health technologies

s, including telemedicine and mobile health apps, are being increasingly integrated into OUD treatment plans. These tools provide remote monitoring, virtual counseling, and personalized treatment adjustments, improving patient engagement and access to care.

• Advancements in Medication-Assisted Treatment (MAT): There have been significant innovations in MAT, including extended-release formulations and novel combination therapies. These advancements enhance treatment adherence and reduce the potential for misuse, offering more effective and long-lasting solutions for managing OUD.
• Focus on Integrated Care Models: Integrated care models that combine OUD treatment with mental health and social support services are gaining traction. This holistic approach addresses the multifaceted needs of patients, improving overall outcomes and reducing the risk of relapse.
• Expansion of Harm Reduction Programs: Harm reduction strategies, such as needle exchange programs and supervised consumption sites, are being expanded. These programs aim to reduce the negative health consequences of drug use and provide pathways to treatment and recovery.
• Emphasis on Personalized Medicine: Personalized medicine approaches, including genetic testing and individualized treatment plans, are becoming more prevalent. These strategies tailor treatment to the specific needs and characteristics of each patient, improving efficacy and minimizing side effects.

These emerging trends are reshaping the OUD market by introducing more effective, personalized, and integrated approaches to treatment. The focus on digital health, advanced medications, and holistic care models reflects a shift towards improving patient outcomes and addressing the complex needs of those affected by opioid use disorder.

Recent Developments in the Opioid Use Disorder (OUD) Market

Recent developments in the opioid use disorder (OUD) market have focused on improving treatment options, expanding access, and enhancing support systems. These changes are driven by the ongoing need to address the opioid crisis and provide effective, comprehensive care.

• Expansion of Medication-Assisted Treatment (MAT): New MAT formulations and extended-release options have been introduced, improving treatment adherence and efficacy. Innovations in buprenorphine and naltrexone formulations offer better management of withdrawal symptoms and relapse prevention.
• Integration of Digital Tools: The adoption of digital health tools, including telemedicine platforms and mobile apps, has enhanced the delivery of OUD treatment. These tools facilitate remote monitoring, virtual counseling, and data-driven adjustments to treatment plans.
• Strengthening Harm Reduction Initiatives: Governments and organizations have increased funding and support for harm reduction programs. Needle exchange programs, supervised consumption sites, and naloxone distribution efforts are expanding, aiming to reduce the negative impact of opioid use.
• Policy and Regulatory Changes: New regulations and policies have been implemented to improve access to OUD treatments and support services. Policies include expanded insurance coverage for MAT and initiatives to reduce stigma and increase public awareness.
• Focus on Integrated Care Models: Integrated care models that combine OUD treatment with mental health and social support services are being promoted. These models address the comprehensive needs of patients and enhance overall treatment effectiveness.

These recent developments reflect a concerted effort to improve OUD treatment and support systems. By focusing on medication advancements, digital tools, harm reduction, policy changes, and integrated care, the market is evolving to better address the complexities of opioid use disorder and support patient recovery.

Strategic Growth Opportunities for Opioid Use Disorder (OUD) Market

The opioid use disorder (OUD) market presents several strategic growth opportunities across various applications. Leveraging these opportunities can enhance treatment outcomes, expand access, and address the ongoing opioid crisis effectively.

• Expansion of MAT Programs: Expanding medication-assisted treatment programs to underserved areas offers significant growth potential. Increasing the availability of MAT options, such as buprenorphine and methadone, can improve access to effective treatment for those struggling with OUD.
• Integration of Digital Health Solutions: The incorporation of digital health solutions, including telemedicine and mobile apps, provides growth opportunities. These tools enhance treatment delivery, patient engagement, and monitoring, creating new avenues for market expansion.
• Development of Novel Therapies: Investing in research and development of novel therapies, such as new drug formulations and combination treatments, presents growth opportunities. Innovative therapies that address unmet needs can capture market share and offer improved treatment options.
• Expansion of Harm Reduction Programs: Expanding harm reduction programs, such as needle exchange services and supervised consumption sites, offers growth opportunities. These programs can reduce the impact of opioid use and provide pathways to treatment and recovery.
• Enhancement of Integrated Care Models: Developing and implementing integrated care models that combine OUD treatment with mental health and social support services presents growth potential. These models improve patient outcomes and address the multifaceted needs of individuals with OUD.

Strategic growth opportunities in the OUD market include expanding MAT programs, integrating digital health solutions, developing novel therapies, scaling harm reduction initiatives, and enhancing integrated care models. These opportunities align with the evolving needs of the market and can drive significant improvements in treatment and recovery outcomes.

Opioid Use Disorder (OUD) Market Driver and Challenges

The opioid use disorder (OUD) market is significantly influenced by various drivers and challenges that encompass technological advancements, economic factors, and regulatory changes. The drivers include innovations in treatment options, increased awareness, policy reforms, economic incentives, and improved access to care. Challenges, on the other hand, involve regulatory hurdles, economic barriers, and issues related to treatment adherence and accessibility. Understanding these factors is crucial for stakeholders aiming to navigate the complexities of the OUD market and enhance strategies for effective treatment and management.

The factors responsible for driving the opioid use disorder (OUD) market include:

1. Technological Advancements: Innovations in treatment technologies, such as digital health tools and advanced medication formulations, are driving growth in the OUD market. Digital platforms facilitate remote monitoring, telemedicine, and personalized treatment plans, improving patient engagement and outcomes. New drug formulations, including extended-release options, enhance the efficacy and convenience of treatment, contributing to increased market demand.

2. Increased Awareness and Education: Growing awareness about the opioid crisis and OUD has led to increased demand for effective treatments. Educational campaigns and public health initiatives are improving understanding of opioid addiction, reducing stigma, and encouraging individuals to seek treatment. This heightened awareness is driving market growth as more people recognize the need for OUD management solutions.

3. Policy and Regulatory Reforms: Changes in policies and regulations are facilitating better access to OUD treatments. Government initiatives, such as expanded insurance coverage for medication-assisted treatment (MAT) and supportive legislation, are reducing barriers to care. These reforms are encouraging healthcare providers to offer a wider range of treatment options and improving overall access for patients.

4. Economic Incentives and Funding: Increased funding from government and private sources is supporting OUD treatment programs and research. Economic incentives, such as subsidies for MAT and grants for addiction treatment facilities, are making it easier for providers to offer comprehensive care. This financial support is driving market growth by enhancing treatment availability and innovation.

5. Expansion of Treatment Access: Efforts to expand access to OUD treatments, particularly in underserved and rural areas, are driving market growth. Initiatives to increase the number of treatment centers, provide mobile treatment units, and integrate care into primary health services are improving accessibility. These efforts are ensuring that more individuals can receive the necessary care for managing OUD.

Challenges in the opioid use disorder (OUD) market include:

1. Regulatory Hurdles: Navigating complex regulatory requirements and obtaining approvals for new treatments can be challenging. Variability in regulations across regions can delay market entry for innovative therapies and create barriers to widespread adoption. Compliance with stringent guidelines can also increase costs for manufacturers and limit treatment availability.

2. Economic Barriers: High costs associated with OUD treatments, including medications and therapy programs, can be a significant barrier. Economic constraints may limit patient access to necessary care and affect treatment adherence. Insufficient insurance coverage and out-of-pocket expenses can further exacerbate these challenges, impacting overall market growth.

3. Treatment Adherence and Accessibility Issues: Ensuring consistent treatment adherence and addressing accessibility issues pose significant challenges. Patients may struggle with adherence due to side effects, stigma, or lack of support. Limited availability of treatment centers, particularly in remote areas, can also hinder access and affect the effectiveness of OUD management efforts.

The opioid use disorder market is shaped by a complex interplay of drivers and challenges. Technological advancements, increased awareness, policy reforms, economic incentives, and expanded access are key drivers that enhance treatment effectiveness and availability. However, regulatory hurdles, economic barriers, and issues with treatment adherence and accessibility present significant challenges. Addressing these factors is crucial for optimizing market strategies and improving outcomes for individuals affected by opioid use disorder. Understanding and navigating these dynamics will be essential for stakeholders seeking to advance the OUD treatment landscape.

List of Opioid Use Disorder (OUD) Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies opioid use disorder (OUD) companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the opioid use disorder (OUD) companies profiled in this report include-

• Hikma Pharmaceuticals
• Indivior
• Titan Pharmaceuticals
• Reckitt Benckiser Pharmaceuticals
• Camurus
• BioDelivery Sciences International
• Sandoz

Opioid Use Disorder (OUD) by Segment

The study includes a forecast for the global opioid use disorder (OUD) by drug type, age group, route of administration, distribution channel, and region.

Opioid Use Disorder (OUD) Market by Drug Type [Analysis by Value from 2018 to 2030]:

• Agonist
• Antagonist

Opioid Use Disorder (OUD) Market by Age Group [Analysis by Value from 2018 to 2030]:

• 19 To 39
• 40 To 59
• Age 60 and Over

List of Opioid Use Disorder (OUD) Companies

Opioid Use Disorder (OUD) Market by Route of Administration [Analysis by Value from 2018 to 2030]:

• Oral
• Intravenous
• Sublingual

Opioid Use Disorder (OUD) Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific

Opioid Use Disorder (OUD) Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Retail Pharmacy

Country Wise Outlook for the Opioid Use Disorder (OUD) Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below is a summary of recent developments by major opioid use disorder producers in key regions: the USA, China, India, Japan, and Germany.

• United States: In the US, there has been a notable increase in the availability of naloxone and buprenorphine, with expanded access through recent legislation. The FDA approved new formulations of buprenorphine for enhanced efficacy and ease of use. Additionally, federal and state governments are implementing comprehensive strategies, including expanded treatment facilities and harm reduction programs.
• China: China has been focusing on improving access to opioid dependence treatments, including methadone maintenance therapy (MMT) and buprenorphine. Recent policy changes have aimed to integrate OUD treatment into broader healthcare services. Efforts to increase public awareness and reduce stigma around addiction are also being emphasized.
• Germany: Germany has advanced its treatment protocols with new guidelines incorporating both pharmacological and psychosocial interventions. The integration of digital health solutions, such as telemedicine for therapy management, has been a key development. Increased funding for addiction treatment services has also been noted.
• India: In India, there is a growing focus on increasing access to OUD treatments, with an emphasis on expanding methadone and buprenorphine programs. Recent developments include the establishment of more treatment centers and community-based programs. Public awareness campaigns are being strengthened to combat stigma and promote treatment options.
• Japan: Japan has introduced new regulations to improve access to opioid treatment programs. There has been an increase in the availability of treatment options such as buprenorphine and extended-release naltrexone. Additionally, efforts to enhance coordination between healthcare providers and support systems have been a focus.

Features of the Global Opioid Use Disorder (OUD) Market

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the opioid use disorder (OUD) market by drug type (agonist and antagonist), age group (19 to 39, 40 to 59, and age 60 and over), route of administration (oral, intravenous, and sublingual), distribution channel (hospital pharmacy and retail pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Opioid Use Disorder (OUD) Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Opioid Use Disorder (OUD) Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Opioid Use Disorder (OUD) Market by Drug Type
  • 3.3.1: Agonist
  • 3.3.2: Antagonist
• 3.4: Global Opioid Use Disorder (OUD) Market by Age Group
  • 3.4.1: 19 to 39
  • 3.4.2: 40 to 59
  • 3.4.3: Age 60 and over
• 3.5: Global Opioid Use Disorder (OUD) Market by Route of Administration
  • 3.5.1: Oral
  • 3.5.2: Intravenous
  • 3.5.3: Sublingual
• 3.6: Global Opioid Use Disorder (OUD) Market by Distribution Channel
  • 3.6.1: Hospital pharmacy
  • 3.6.2: Retail Pharmacy

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Opioid Use Disorder (OUD) Market by Region
• 4.2: North American Opioid Use Disorder (OUD) Market
  • 4.2.1: North American Market by Drug Type: Agonist and Antagonist
  • 4.2.2: North American Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy
• 4.3: European Opioid Use Disorder (OUD) Market
  • 4.3.1: European Market by Drug Type: Agonist and Antagonist
  • 4.3.2: European Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy
• 4.4: APAC Opioid Use Disorder (OUD) Market
  • 4.4.1: APAC Market by Drug Type: Agonist and Antagonist
  • 4.4.2: APAC Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy
• 4.5: ROW Opioid Use Disorder (OUD) Market
  • 4.5.1: ROW Market by Drug Type: Agonist and Antagonist
  • 4.5.2: ROW Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Age Group
  • 6.1.3: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Route of Administration
  • 6.1.4: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Distribution Channel
  • 6.1.5: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Region
• 6.2: Emerging Trends in the Global Opioid Use Disorder (OUD) Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Opioid Use Disorder (OUD) Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Opioid Use Disorder (OUD) Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Hikma Pharmaceuticals
• 7.2: Indivior
• 7.3: Titan Pharmaceuticals
• 7.4: Reckitt Benckiser Pharmaceuticals
• 7.5: Camurus
• 7.6: BioDelivery Sciences International
• 7.7: Sandoz